e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Immune-mediated interstitial lung diseases: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Interstitial lung disease associated with ANCA positivity: a retrospective analysis
S. Juman (Manchester, United Kingdom), S. Haque (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
Source:
International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Session:
Immune-mediated interstitial lung diseases: from bench to bedside
Session type:
Thematic Poster
Number:
1362
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Juman (Manchester, United Kingdom), S. Haque (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom). Interstitial lung disease associated with ANCA positivity: a retrospective analysis. 1362
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Nine cases of interstitial lung disease associated with anti-CADM140 antibody positive dermatomyositis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
A clinicopathological review of interstitial pneumonia with marked IgG
4
positive plasma cells infiltration
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Incidence, prevalence and mortality of rheumatoid arthritis-associated interstitial lung disease : a retrospective study
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021
Diffuse interstitial lung disease (a retrospective analysis of 79 cases)
Source: Eur Respir J 2002; 20: Suppl. 38, 61s
Year: 2002
Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
The analysis of prognostic factors in patients with interstitial lung diseases
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Multidisciplinary diagnosis of interstitial lung disease: a retrospective analysis
Source: International Congress 2019 – Medical education
Year: 2019
Long-term outcome of 53 patients with anti-Jo-1 antibody-positive interstitial lung disease
Source: International Congress 2017 – Rare diseases
Year: 2017
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Myositis-associated interstitial pneumonia (MaIP): Autoantibody associations in patients presenting to pulmonologists and rheumatologists
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
Source: Breathe, 16 (1) 190321; 10.1183/20734735.0321-2019
Year: 2020
Interstitial lung disease associated with polymyositis-dermatomyositis
Source: Eur Respir J 2005; 26: Suppl. 49, 31s
Year: 2005
A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Radiologic pattern as a survival predictor in the rheumatoid artritis intersticial lung disease
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody
Source: Eur Respir Rev 2015; 24: 370-372
Year: 2015
The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Prognostic significance of pathologically proven chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs): single center retrospective cohort
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept